Ads
related to: cyberknife treatment prostate cancer results interpretation guidelines- Side Effect Information
Learn More About Potential Side
Effects And Safety Information.
- Oral Medication
Learn More About An Oral Treatment
For Metastatic Prostate Cancer.
- Genomic Testing
Read How Testing Could
Help Inform Your Treatment Plan.
- Patient Support Program
Learn About A Treatment Option
And Patient Support.
- Side Effect Information
Search results
Results From The WOW.Com Content Network
Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.
Her expertise includes treatment of brain tumors. In 2010, Dr. Fleming and Dr. Tay were among the founding doctors of Saint Mary’s Brain Tumor Center. [5] The center was the region’s first brain tumor center. Reno CyberKnife provides all stereotactic radiosurgery treatment for Saint Mary’s Brain Tumor Center patients who are candidates.
Surgical removal of the prostate, or prostatectomy, is a common treatment either for early-stage prostate cancer or for cancer that has failed to respond to radiation therapy. The most common type is radical retropubic prostatectomy , when the surgeon removes the prostate through an abdominal incision.
The inaugural CyberKnife system was installed at Stanford University in 1991, receiving clearance for clinical investigation by the U.S. Food and Drug Administration (FDA) in 1994. Following extensive clinical research, the FDA granted approval for the treatment of intracranial tumors in 1999 and for tumors throughout the body in 2001 ...
Oklahoma CyberKnife is a cancer treatment center based in Oklahoma. The center treats malignant and benign tumors in the lungs, spine, brain, liver, pancreas, eye, prostate and kidney using CyberKnife technology. Oklahoma CyberKnife has treated patients from around Oklahoma as well as patients from bordering states.
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...